  Molecular and immune therapies have revolutionized cancer treatment and improved patient outcomes and survival. However , the pricing of these drugs has become an issue as the cost of cancer care continues to rise significantly. Cost sharing policies have increased out-of-pocket expenses for patients , leading to poorer financial well-being , quality of life , psychosocial health , and treatment adherence. In this review , we briefly examine some factors affecting the pricing of these new targeted therapies; the effects of financial toxicity on patients; and highlight potential health policy and patient-provider level interventions to address these issues.